Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G:超過5%持股股東披露文件-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q:2024財年三季報
Larimar Therapeutics | 8-K:Larimar Therapeutics公佈2024年第三季度運營和財務業績
Larimar Therapeutics | 10-Q:2024財年二季報
Larimar Therapeutics | 8-K:Larimar Therapeutics公佈2024年第二季度運營和財務業績
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 4:持股變動聲明-董事 Flynn James E
Larimar Therapeutics | 4:持股變動聲明-董事 Hamilton Thomas Edward
Larimar Therapeutics | 4:持股變動聲明-董事 Truitt Joseph
Larimar Therapeutics | 4:持股變動聲明-董事 SHERMAN JEFFREY W
Larimar Therapeutics | 4:持股變動聲明-董事 LEFF JONATHAN S
Larimar Therapeutics | 4:持股變動聲明-董事 THOMAS FRANK E
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | EFFECT:其他
Larimar Therapeutics | CORRESP:信函
暫無數據
暫無數據